---

$1.42

+0.2550 ( -27.06% ) 759.0K

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-08-13	Buy	100.00	FRIEDBERG ALBERT
2024-08-07	Buy	3653.00	FRIEDBERG ALBERT
2024-08-02	Buy	11703.00	FRIEDBERG ALBERT
2024-08-01	Buy	100629.00	FRIEDBERG ALBERT
2024-05-31	Buy	957.00	FRIEDBERG ALBERT
2024-05-14	Sale	-543.00	Van Strydonck, Gerald E.
2024-05-14	Sale	-2685.00	MANIAN BALA S
2024-05-14	Sale	-10108.00	Stecyk Chrystyna Bedrij
2024-05-14	Sale	-2211.00	Frieberg Jacob B.
2024-05-14	Sale	-10108.00	Yanni Barbara

Reset

Symbol	Issuer Name	Market Value ↓	Share Quantity
No records found.